Is a 4 mg dose of Rexulti (brexpiprazole) too high?

Is 4 mg of Rexulti Too High?

No, 4 mg of Rexulti (brexpiprazole) is not too high—it falls within the FDA-approved therapeutic range and represents the maximum recommended dose for schizophrenia (1-4 mg/day) and is above the maximum for major depressive disorder (2-3 mg/day) and Alzheimer's-related agitation (2-3 mg/day). 1

FDA-Approved Dosing by Indication

The appropriateness of 4 mg depends entirely on the indication:

Schizophrenia

• Recommended dose range: 1-4 mg once daily 1
• Target dose: 2-4 mg/day 1
• Titration schedule: Start 1 mg/day, increase to 2 mg on days 5-7, then to 4 mg on day 8 1
• 4 mg is appropriate and within therapeutic range 1, 2, 3

Major Depressive Disorder (Adjunctive)

• Recommended dose range: 0.5-3 mg once daily 1
• Target dose: 2 mg/day 1
• Maximum dose: 3 mg/day 1
• 4 mg exceeds the approved maximum for MDD 1

Agitation in Alzheimer's Dementia

• Recommended dose range: 0.5-3 mg once daily 1
• Target doses: 2-3 mg/day 1
• Maximum dose: 3 mg/day 1
• 4 mg exceeds the approved maximum for this indication 1

Efficacy Evidence at 4 mg

Both 2 mg and 4 mg doses demonstrate comparable efficacy for schizophrenia:

• In acute schizophrenia trials, 4 mg showed statistically significant improvement versus placebo (treatment difference: -7.64 on PANSS total score) 2
• Another trial demonstrated 4 mg superiority with treatment difference of -6.47 (p=0.0022) 3
• Meta-analysis showed both 2 mg and 4 mg had identical effect sizes (SMD = -0.30) for PANSS total scores 4
• Response rates were 46% for brexpiprazole 2-4 mg/day versus 31% for placebo (NNT=7) 5

Safety Considerations at 4 mg

The 4 mg dose carries a higher risk of extrapyramidal symptoms compared to 2 mg:

• Akathisia incidence: 7.2% at 4 mg versus 4.4% at 2 mg versus 2.2% placebo 2
• 4 mg was associated with higher risk of extrapyramidal symptoms than 2 mg 4
• Weight gain was moderate and similar between doses: 1.28 kg at 4 mg versus 1.45 kg at 2 mg versus 0.42 kg placebo at 6 weeks 2
• Long-term weight gain at 52 weeks averaged 2.1 kg 6
• No clinically relevant QTc prolongation at doses 3 times the maximum recommended dose 1

Dose Adjustments Required

Reduce the dose to 2 mg (half of 4 mg) in the following situations: 1

• Moderate to severe hepatic impairment (Child-Pugh ≥7): Maximum 3 mg for schizophrenia 1
• Moderate renal impairment (CrCl <60 mL/min): Maximum 3 mg for schizophrenia 1
• CYP2D6 poor metabolizers: Administer half the recommended dose 1
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): Administer half dose 1
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Administer half dose 1

Reduce to 1 mg (quarter of 4 mg) when: 1

• CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors 1
• Strong/moderate CYP2D6 inhibitors combined with strong/moderate CYP3A4 inhibitors 1

Clinical Decision Algorithm

For schizophrenia patients:

1. If no response at 2 mg after 4 weeks with confirmed adherence, consider increasing to 4 mg 7
2. If patient was previously on a D2 partial agonist (like aripiprazole) without adequate response, consider switching to a different pharmacodynamic profile rather than maximizing brexpiprazole dose 7
3. Monitor for akathisia and extrapyramidal symptoms more closely at 4 mg 4, 2

For MDD or Alzheimer's agitation:

• 4 mg is above the approved maximum and should not be used 1
• Maximum doses are 3 mg for these indications 1

Common Pitfalls

• Using 4 mg for indications other than schizophrenia exceeds FDA approval 1
• Failing to adjust dose for hepatic/renal impairment or drug interactions can lead to excessive drug exposure 1
• Not accounting for CYP2D6 poor metabolizer status (7-10% of Caucasians) can result in 2-fold higher exposure 1
• The long half-life (91 hours) means steady-state takes 10-12 days, so dose adjustments should not be made more frequently 1